CI-994 HDAC Inhibitor Modulates Histone Acetylation for Cognitive Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cognitive function disorders and memory impairments associated with conditions like Alzheimer's disease and Huntington's disease are inadequate, with no known cure and limited understanding of the underlying causes, and existing histone deacetylase inhibitors have not shown significant efficacy in improving cognitive function.
Innovation Solution
Administration of 4-(acetylamino)-N-(2-aminophenyl)benzamide (CI-994) or its metabolite dinaline, primarily as Class I HDAC inhibitors, to modulate histone acetylation, which is believed to enhance cognitive function and treat cognitive disorders through various routes of administration, including oral, transdermal, and intracerebroventricular, with specific dosing regimens and combinations with behavioral therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing histone deacetylase inhibitors are used to treat cognitive function disorders, then histone deacetylation is inhibited, but significant improvement in cognitive function is not achieved
Solution Approach 1:
The patent changes the chemical structure parameters of HDAC inhibitors by introducing a naphthalene sulfonamide core structure with specific substituents (amino group at position 2, aryl or heteroaryl group at position 4), transforming existing ineffective inhibitors into compounds that significantly improve cognitive function and promote fear extinction
Solution Approach 2:
The patent applies local quality by specifically targeting Class I HDAC enzymes (HDAC1, HDAC2, HDAC3) with selective inhibition, where HDAC2 inhibition appears particularly important for cognitive function improvement and fear extinction, rather than non-selectively inhibiting all HDAC classes
2Reliability
If high doses of CI-994 are administered to improve cognitive function, then cognitive improvement is achieved, but dosage and potential side effects increase
Solution Approach 1:
The patent optimizes the dosage parameter by establishing effective dose ranges (0.1-10 mg/kg, preferably 0.5-5 mg/kg, most preferably 1-2.5 mg/kg) that achieve cognitive improvement and fear extinction while minimizing potential side effects, representing a significant reduction from higher experimental doses
3Reliability
If CI-994 is administered to promote fear extinction, then fear memory is reduced, but understanding of the mechanism remains limited
Solution Approach 1:
The patent employs feedback mechanisms by using behavioral assays (fear conditioning, extinction testing) to monitor and evaluate the effectiveness of CI-994 treatment, allowing optimization of dosage and treatment duration based on observed fear extinction responses
Solution Approach 2:
The patent segments the complex mechanism into identifiable components: HDAC inhibition → increased histone acetylation → enhanced gene transcription → improved cognitive function and fear extinction, allowing targeted investigation of each step
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
CI-994 demonstrates significant improvement in cognitive function and memory formation, even at low doses, with increased histone acetylation marks and effective brain penetration, offering a potential therapeutic approach for conditions such as Alzheimer's and Huntington's disease, as well as fear extinction and other cognitive impairments.
Implementation Method 1
CI-994 and dinaline are believed to improve cognitive function in part through inhibition of histone deacetylase, resulting in increased histone acetylation
Data Source
AI summary
The invention relates to methods and compositions for promoting cognitive function and/or treating cognitive function disorders and impairments. In particular the methods are accomplished by administering to a subject CI-994 or dinaline or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof.